Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions

Anne-Hilde Muris*, Linda Rolf, Jan Damoiseaux, Ellen Koeman, Raymond Hupperts

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on MRI as compared to either interferon beta (IFN beta) or placebo. The effect of fingolimod on MRI outcomes compared to natalizumab treatment has not been investigated in (head to head) clinical trials. Clinical experience with natalizumab is much more extended and in general practice often preferred. Case presentation: This case describes a 31-year old woman with RRMS, who experienced severe side effects on natalizumab. After a voluntary four months treatment free period, a severe relapse appeared which was treated with prednisone and plasmapheresis; thereafter fingolimod was initiated. In the following months MRI signs improved spectacularly. Conclusion: This case suggests that fingolimod might be a good alternative for natalizumab, especially for use in RRMS patients, with highly active, advanced disease, when natalizumab treatment is stopped due to side effects or even after a severe relapse.
Original languageEnglish
Article number164
JournalBMC Neurology
Publication statusPublished - 20 Aug 2014


  • Disease modifying therapies
  • Fingolimod
  • Multiple sclerosis
  • MRI
  • Relapsing remitting
  • T1gadolinium enhancing lesions
  • T2 lesions

Cite this